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Abstract
Background: Medication errors, adverse drug events and potential adverse drug events are
common and serious in terms of the harms and costs that they impose on the health system and
those who use it. Errors resulting in preventable adverse drug events have been shown to occur
most often at the stages of ordering and administration. This paper describes the protocol for a
pragmatic trial of electronic prescribing to reduce prescription error. The trial was designed to
overcome the limitations associated with traditional study design.
Design: This study was designed as a 65-week, cluster randomized, parallel study.
Methods: The trial was conducted within ambulatory outpatient clinics in an academic tertiary
care centre in Ontario, Canada. The electronic prescribing software for the study is a Canadian
electronic prescribing software package which provides physician prescription entry with decision
support at the point of care. Using a handheld computer (PDA) the physician selects medications
using an error minimising menu-based pick list from a comprehensive drug database, create specific
prescription instructions and then transmit the prescription directly and electronically to a
participating pharmacy via facsimile or to the physician's printer using local area wireless
technology. The unit of allocation and randomization is by 'week', i.e. the system is "on" or "off"
according to the randomization scheme and the unit of analysis is the prescription, with adjustment
for clustering of patients within practitioners.
Discussion: This paper describes the protocol for a pragmatic cluster randomized trial of point-
of-care electronic prescribing, which was specifically designed to overcome the limitations
associated with traditional study design.
Trial Registration: This trial has been registered with clinicaltrials.gov (ID: NCT00252395)
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Background & rationale
A medication error, as defined by the National Coordinat-
ing Council for Medication Error Reporting and Preven-
tion (NCCMERP), is a preventable event that may cause or
lead to inappropriate medication use or patient harm.
Such events may be related to practice, products, proce-
dures, and systems, including prescribing, order commu-
nication, product labelling, packaging, nomenclature,
compounding, dispensing, distribution, administration,
education, monitoring, and use [1].
Medication errors, adverse drug events (ADEs), and
potential adverse drug events impose substantial harms
and costs on patients and the health system. The largest
study [2] of the prevalence of ADEs and potential ADEs
suggests rates of 6.5 ADEs and 5.5 potential ADEs per 100
hospital admissions. Of the life-threatening and serious
ADEs in this study, 42% were preventable, compared with
18% of significant ADEs. Errors resulting in preventable
ADEs occurred most often at the stages of ordering (56%)
and administration (34%); transcription (6%) and dis-
pensing errors (4%) were less common.
There are little data available on errors (as distinct from
ADEs, which reflect actual harm). In one study [3] of 36
participating inpatient institutions, 605 (19%) of 3216
medication doses were given in error. Seven percent of
these errors were found to be potentially harmful to
patients. However, this study was designed to capture
only dispensing errors and not prescribing errors.
Changing clinical practices in the area of prescribing error
has been widely discussed. In general, it is thought that
systems changes rather than individual educational inter-
ventions will be required to trap errors, and the main solu-
tion widely discussed is the use of computerized physician
order entry (CPOE).
There is reliable evidence that computerized order entry
reduces ADEs, but the systems used to date have all been
desktop-based. In a systematic review [4] of well-con-
ducted evaluations (one of which was a randomized trial)
of physician order entry systems and a recent Canadian
randomized trial, the separate studies showed findings
such as 81% decrease in total medication errors, 55%
decrease in non-intercepted serious medication errors,
13% decrease in cases of inappropriate dosing and 24%
decrease in inappropriate frequency of nephrotoxic drugs,
all of which were statistically significant. These are sub-
stantial benefits, with a median of 55% improvement.
These studies and their resultant benefits were obtained in
the inpatient setting, where the sheer intensity of prescrib-
ing and complexity of patient condition could be expected
to result in much higher levels of error. However, there is
no reason to believe that the relative benefit obtained in a
high intensity setting cannot also be obtained in a lower
intensity one.
All reliably evaluated CPOE systems to date have been
desktop computer based, but there is widespread use and
acceptance among physicians of PDAs (personal digital
assistants), in many roles. Clinicians report that drug
information on a PDA improved their access to informa-
tion and efficiency while reducing their self-perceived
error rates [5]. The use of these devices for information
retrieval in clinical settings is expected to grow as wireless
communication becomes more ubiquitous and as more
applications become available [5,6]. During the past dec-
ade there has been a growing awareness of several inter-
ventions, such as point of care information technology,
aimed at promoting safer health care for our patients. As
far as we are aware, our study is the first to rigorously eval-
uate PDA-based prescribing systems in which drug inter-
action, dosing alerts, and adverse event reporting are fully
integrated.
This paper describes the protocol for a pragmatic cluster
randomized trial of point-of-care electronic prescribing,
which was specifically designed to overcome the limita-
tions associated with traditional study design.
Methods
This study was approved by both the participating hospi-
tal and the University of Toronto research ethics boards. A
standing advisory committee provided input into the
design and conduct of the study since inception and has
continued to meet regularly during the implementation.
This trial has also been registered with clinicaltrials.gov
(identifier NCT00252395).
The Intervention
A field-tested Canadian electronic prescribing software
package (Drugmagnet, Toronto, Ontario) designed for
physician prescription entry with decision support at the
point of care was used for this study. A physician, using a
battery powered PDA (Palm Pilot or equivalent) selects
medications using an error minimising menu-based pick
list from a comprehensive drug database, creates specific
prescription instructions and then transmits the prescrip-
tion directly and electronically to a participating phar-
macy via facsimile or to the physician's printer using local
area wireless technology. Each prescription order is
checked against stored evidence-based guidelines and a
dosing and interactions database.
Study population
This trial has been conducted within ambulatory outpa-
tient clinics at an academic health sciences centre in
Toronto, Ontario, Canada (August 2005 – October 2006).
Both a specialist setting (Rheumatology, DermatologyTrials 2007, 8:28 http://www.trialsjournal.com/content/8/1/28
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and Cardiology patients) and a primary care Family Med-
icine setting were used. There are approximately 40 full-
time physicians within these clinics, who see a total of
approximately 1000 patients each week.
Study design
The study was a 65-week, cluster randomized (3:1 alloca-
tion ratio), parallel study with time as the element of ran-
domization. The randomization scheme was computer
generated by the biostatistics department at the hospital.
The unit of allocation and randomization was the 'week';
although the unit of analysis is the prescription, with
adjustment for clustering of patients within physicians.
All participating physicians were trained to use electronic
prescribing software, but only half of the weeks in the
study period were allocated as intervention or "on" weeks,
during which the software was switched on, and prescrib-
ing was carried out electronically.
Physician training consisted of a simple two hour training
course and follow-up tutoring where necessary. The
Health Informatician on the project used regular check-
ins and a help-line pager to ensure that all technical issues
were fixed in a timely manner and that any prevalent user
errors with regard to the software were addressed. No fur-
ther training was conducted in order simulate real-world
conditions with limited user support.
During control periods all prescriptions were written on
paper as per standard practice. During intervention peri-
ods or "on" weeks, all prescriptions were to be filled using
the PDAs and the electronic prescribing software. The ran-
domization was employed by turning the prescribing soft-
ware servers in each clinic on and off according to the
randomization scheme. A health informatics assistant was
responsible for carrying out the randomization and the
allocation was kept concealed until midnight on the last
day of the previous week. If a physician tried to enter a
prescription on his or her handheld on a control or "off"
week, the system immediately gave a message that the
wireless network was not been detected, and that the soft-
ware was inaccessible.
Outcomes
The principle outcome measure was total prescribing
error, as measured by the number of call backs received
from pharmacists to prescribing physicians offices. These
are defined as potential medication errors picked up by
the pharmacist at the time the prescription is filled. Rates
will be compared between intervention and control
weeks. Prescribing errors can take many forms and are of
different levels of severity and a single prescription can
have several errors and all will be counted. The denomi-
nator for total error is the total number of prescriptions
and the numerator is the sum of the following types of
error:
a) Interactions
These include errors in which interacting drugs are pre-
scribed, and these interactions can vary between minor
and major. Four standard levels are described- severe, in
which harm is likely; moderate, in which harm may occur
in some situations, but it is reasonable for the physician
to prescribe the drug provided that special monitoring or
other interventions are simultaneously indicated; poten-
tial drug interactions in which an interaction is theoreti-
cally possible, but unlikely or likely but of trivial
importance; and extremely rare potential interaction. All
of the above will be counted in the data analysis.
b) Dosing and route of administration errors
These are errors in which the prescribed dose or route of
administration are incompatible with the recommended
guidelines for that patient, based on weight, concurrent
drugs or illnesses, and age.
c) Legibility
These are errors in which the writing on the prescription
is not easily legible, in the pharmacist's opinion.
Sample size and analysis plan
The unit of analysis for this trial is the individual prescrip-
tion, adjusting for clustering of patients within physicians.
Given an estimated intra-class correlation value of 0.05, a
minimum of 65 weeks of prescribing is required to have
80% power for a two sided test to detect an absolute
decrease of 5% from with a control baseline error rate of
25% with a type I error of 5%.
Descriptive statistics will be calculated for all variables of
interest. Continuous measures will be summarized using
means and standard deviations whereas categorical meas-
ures will be summarized using counts and percentages.
The principal outcome measure, total prescribing error
using PDA-generated versus written prescriptions, will be
assessed using a two sample, two-sided test of propor-
tions. This analysis will be performed on an intention-to-
treat basis. All analyses will be carried out using the SAS
Version 9.1 statistical program (SAS Institute, Cary, NC,
USA).
Data collection
Data on prescription errors was captured in two formats.
One set of data consisted of data points recorded on a
form during callbacks to the participating physicians'
offices from pharmacies regarding prescription errors. A
second set of data was derived from forms completed by
the hospital internal pharmacy for each prescription filled
there. These forms also include indicators related to pre-Trials 2007, 8:28 http://www.trialsjournal.com/content/8/1/28
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scribing errors and legibility. Data forms were collected
weekly and transcribed into a database for analysis.
To guarantee privacy and confidentiality, all research data
were kept within the hospital by professional staff operat-
ing under codes of conduct and using encrypted data cap-
ture systems. All patient and prescription data were
anonymized after linkage. The electronic prescribing tech-
nology uses the highest existing levels of data encryption
and its mode of operation conforms to professional obli-
gations on confidentiality and Canadian and Ontario pri-
vacy laws.
Discussion
This trial will be able to evaluate electronic prescribing in
a hospital setting effectively while preserving the benefits
of randomization to reduce bias. Its design takes into
account the need for internal and external validity, that
the results are attributable to the intervention and that
they may be applied to general practice. This design is
practical and does not interfere with usual physician
workflow.
The findings from this trial will provide important infor-
mation about the role of electronic prescribing in the
ambulatory setting for clinicians and healthcare policy-
makers in distinguishing.
One of the key decisions that required consideration in
the design of this trial was the question of the appropriate-
ness of physician- or cluster-level randomization. Rather
than allocating physicians between the two groups using
a random process, cluster-level randomized trials allocate
groups of participants. In this study we randomized by
time periods. The rationale for this randomization
scheme is apparent when there is a high risk of heteroge-
neity between groups and to allow for the participating
physicians to serve as their own controls groups.
This study will be the first published randomized control
trial designed to evaluate the effectiveness of electronic
prescribing in reducing prescription error in an ambula-
tory setting. Although technology applications related to
patient safety and human error reduction are sweeping the
healthcare landscape, it is important that we do not fall in
to the same trap as our forefathers did with medications
and snake oils. It is as important if not imperative to rig-
orously evaluate these applications in pragmatic, real-
world fashion so that we can determine if they are truly
effective or more of a hindrance than help. We look for-
ward to adding the results of this trial to the growing body
of literature in this area.
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